Schistosomiasis Cell Models for Research

Schistosomiasis is a neglected tropical disease caused by parasitic flatworms of the genus Schistosoma. According to the World Health Organization (WHO), over 250 million people required preventive treatment in 2021, with more than 200,000 deaths annually. The disease is endemic in 78 countries, primarily in sub-Saharan Africa, where Schistosoma mansoni and Schistosoma haematobium are prevalent. Key risk factors include contact with freshwater contaminated with cercariae, poor sanitation, and agricultural practices. Unlike many infectious diseases, schistosomiasis does not have a 5-year survival metric; however, chronic infection leads to severe morbidity, including liver fibrosis, bladder cancer, and renal failure. The WHO aims to eliminate schistosomiasis as a public health problem by 2030, underscoring the need for new interventions.

Schistosomiasis serves as a valuable model for studying host-parasite interactions, immune evasion, and fibrosis. The availability of genomic data for Schistosoma mansoni, S. japonicum, and S. haematobium (NCBI Gene, UniProt) enables functional studies. Public datasets such as those from the Wellcome Sanger Institute and the Schistosoma mansoni Genome Project provide a foundation for target discovery. Open questions include the mechanisms of granuloma formation, parasite-induced carcinogenesis (e.g., bladder squamous cell carcinoma in S. haematobium infection), and drug resistance to praziquantel. These factors make schistosomiasis an ideal candidate for gene-editing approaches to dissect molecular pathways and identify novel drug targets.

Schistosoma haematobium infection is classified as a Group 1 carcinogen by IARC, primarily associated with bladder squamous cell carcinoma. Key pathways include:

1. Chronic inflammation and oxidative stress: Parasite eggs induce a Th2-dominated immune response, leading to granuloma formation and release of reactive oxygen species, causing DNA damage.

2. Wnt/β-catenin signaling: Upregulated in schistosome-associated bladder cancer, promoting cell proliferation.

3. PI3K/AKT/mTOR pathway: Activated in response to parasite antigens, enhancing survival and metabolic reprogramming.

4. MAPK/ERK pathway: Induced by egg antigens, contributing to fibrosis and tumorigenesis.

These pathways are potential targets for therapeutic intervention and can be modeled using gene-edited cell lines.

Genetic alterations in host cells during schistosomiasis-associated carcinogenesis are less characterized than in other cancers, but studies (e.g., TCGA, COSMIC) reveal recurrent mutations. The table below summarizes key alterations observed in schistosome-associated bladder cancer.

Note: Frequencies are approximate and based on limited studies; further research is needed.

Several signaling networks are deregulated in schistosomiasis-associated pathology:

• • Wnt/β-catenin: Activated by parasite antigens; key nodes include β-catenin, APC, GSK-3β.
• • PI3K/AKT/mTOR: Promotes survival and metabolism; nodes: PI3K, AKT, mTOR, PTEN.
• • MAPK/ERK: Drives inflammation and fibrosis; nodes: RAS, RAF, MEK, ERK.
• • JAK/STAT: Mediates immune evasion and Th2 responses; nodes: JAK1/2, STAT3/6.
• • TGF-β/SMAD: Induces fibrosis; nodes: TGF-β, SMAD2/3, SMAD4.

These networks can be interrogated using CRISPR knockout and knock-in models to identify critical nodes for therapeutic targeting.

Cell lines derived from schistosome-associated cancers are limited, but several models exist for studying host-parasite interactions. The table below lists commonly used cell lines.

Organoids derived from patient bladder or liver tissues are increasingly used to model schistosomiasis-associated carcinogenesis, offering 3D architecture and patient-specific genetics. These models can be genetically modified using CRISPR to study gene function.

Animal models are essential for studying schistosomiasis pathogenesis and evaluating interventions:

• • Patient-derived xenografts (PDX): Implanted human tumor tissues into immunodeficient mice; useful for drug testing but lack immune components.
• • Genetically engineered mouse models (GEMM): Mice with targeted mutations (e.g., Tp53 knockout) to study cancer development in the context of infection.
• • Induced models: Infection of mice with S. mansoni or S. haematobium to mimic human disease, including granuloma formation and fibrosis.
• • Humanized mice: Reconstituted with human immune cells to study immune responses.

These models complement gene-edited cell lines for translational research.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockout of tumor suppressors or knock-in of oncogenic mutations. For schistosomiasis research, relevant models include:

• • TP53 knockout bladder cell lines to study genomic instability induced by parasite antigens.
• • PIK3CA E545K knock-in in bladder epithelial cells to model PI3K/AKT activation.
• • FGFR3 S249C knock-in to mimic bladder cancer mutations.
• • CDKN2A knockout to study cell cycle deregulation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible tools for target validation and drug screening. These models are generated using CRISPR and validated by sequencing and functional assays, ensuring reliability.

Gene-edited cell lines enable functional validation of candidate genes identified from genomic studies. For example, knockout of TP53 in bladder cells can confirm its role in schistosome-associated carcinogenesis. Knock-in of PIK3CA mutations can assess their oncogenic potential. These models facilitate high-throughput screens to identify genes essential for parasite-induced transformation.

Isogenic pairs (e.g., wild-type vs. mutant) are powerful for drug screening. For instance, comparing FGFR3-mutant and wild-type cells can identify selective inhibitors. Resistance modeling involves generating resistant lines through chronic drug exposure and then using CRISPR to identify mechanisms. Such studies can repurpose existing drugs or discover new ones for schistosomiasis-associated complications.

CRISPR synthetic lethality screens in gene-edited cells can uncover vulnerabilities specific to schistosome-infected cells. For example, knocking out DNA repair genes in TP53-mutant cells may reveal synthetic lethal interactions, leading to biomarkers for early detection or targets for therapy. These screens are scalable and can be performed in relevant cell backgrounds.